Jean Laverdière, Maxime Meloche, Sylvie Provost, Grégoire Leclair, Essaïd Oussaïd, Martin Jutras, Louis-Philippe Lemieux Perreault, Diane Valois, Ian Mongrain, David Busseuil, Jean Lucien Rouleau, Jean-Claude Tardif, Marie-Pierre Dubé, Simon de Denus
{"title":"Pharmacogenomic markers of metoprolol and α-OH-metoprolol concentrations: a genome-wide association study.","authors":"Jean Laverdière, Maxime Meloche, Sylvie Provost, Grégoire Leclair, Essaïd Oussaïd, Martin Jutras, Louis-Philippe Lemieux Perreault, Diane Valois, Ian Mongrain, David Busseuil, Jean Lucien Rouleau, Jean-Claude Tardif, Marie-Pierre Dubé, Simon de Denus","doi":"10.2217/pgs-2023-0067","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Few genome-wide association studies (GWASs) have been conducted to identify predictors of drug concentrations. The authors therefore sought to discover the pharmacogenomic markers involved in metoprolol pharmacokinetics. <b>Patients & methods:</b> The authors performed a GWAS of a cross-sectional study of 993 patients from the Montreal Heart Institute Biobank taking metoprolol. <b>Results:</b> A total of 391 and 444 SNPs reached the significance threshold of 5 × 10<sup>-8</sup> for metoprolol and α-OH-metoprolol concentrations, respectively. All were located on chromosome 22 at or near the <i>CYP2D6</i> gene, encoding CYP450 2D6, metoprolol's main metabolizing enzyme. <b>Conclusion:</b> The results reinforce previous findings of the importance of the <i>CYP2D6</i> locus for metoprolol concentrations and confirm that large biobanks can be used to identify genetic determinants of drug pharmacokinetics at a GWAS significance level.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0067","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Few genome-wide association studies (GWASs) have been conducted to identify predictors of drug concentrations. The authors therefore sought to discover the pharmacogenomic markers involved in metoprolol pharmacokinetics. Patients & methods: The authors performed a GWAS of a cross-sectional study of 993 patients from the Montreal Heart Institute Biobank taking metoprolol. Results: A total of 391 and 444 SNPs reached the significance threshold of 5 × 10-8 for metoprolol and α-OH-metoprolol concentrations, respectively. All were located on chromosome 22 at or near the CYP2D6 gene, encoding CYP450 2D6, metoprolol's main metabolizing enzyme. Conclusion: The results reinforce previous findings of the importance of the CYP2D6 locus for metoprolol concentrations and confirm that large biobanks can be used to identify genetic determinants of drug pharmacokinetics at a GWAS significance level.
期刊介绍:
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.